Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer.
Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.
['Sanchala|Dhaval|D|', 'Bhatt|Lokesh K|LK|', 'Prabhavalkar|Kedar S|KS|']
D000970:Antineoplastic Agents D000074322:Antineoplastic Agents, Immunological D002289:Carcinoma, Non-Small-Cell Lung D019008:Drug Resistance, Neoplasm D010450:Endopeptidases D056827:Endosomal Sorting Complexes Required for Transport D066246:ErbB Receptors D018841:HSP90 Heat-Shock Proteins D056572:Histone Deacetylase Inhibitors D006801:Humans D008175:Lung Neoplasms D058990:Molecular Targeted Therapy D009154:Mutation D047428:Protein Kinase Inhibitors D043222:Ubiquitin Thiolesterase
epidermal growth factor receptor Lung cancer epidermal growth factor receptor protein-tyrosine kinase heat-shock protein histone deacetylase monoclonal
antibodies ubiquitin.